Unravelling metabolites conferring intestinal protection in asymptomatic first-degree relatives of patients with celiac disease.
FDRs of celiac disease patients exhibit a unique metabolic profile that may help protect their intestinal integrity despite genetic risk factors.
Where it sits
this study against the rest of the matrixyl corpusSummary and findings
This study investigated the metabolome of serologically negative first-degree relatives (FDRs) of celiac disease (CeD) patients, comparing them with CeD patients and controls. The analysis included 50 FDRs, 64 CeD patients, and 67 controls using proton NMR spectroscopy. Significant metabolic differences were observed, suggesting potential protective mechanisms in FDRs.
Abstract
Celiac disease (CeD) is an autoimmune enteropathy; nearly 60-80% of first-degree relatives (FDRs) of CeD patients carry HLA-DQ2/DQ8 haplotypes; however, only 7.5% of them develop enteropathy. This suggests the modulation of biochemical and molecular mechanisms that might help in maintaining intestinal integrity. Thus, the present study investigated the metabolome of FDRs to gain insight into biochemical mechanisms that might help in maintaining intestinal integrity. The metabolome of small intestinal mucosal biopsies, blood plasma and urine of serologically negative first-degree relatives (FDRs, n = 50) was investigated using proton NMR spectroscopy and compared with CeD patients (n = 64) and controls (disease controls, n = 35 or healthy controls, n = 32) using both univariate and multivariate statistical analyses. The metabolic profiles of FDRs of CeD patients differed significantly from both CeD patients and controls. Higher myo-inositol and fumarate in the mucosa of FDRs suggest the role of these metabolites in modulating the immune response and inflammation, which may protect intestinal integrity in FDRs. Elevated formate and tyrosine levels in the intestinal mucosa of FDRs, compared to both CeD patients and controls, suggested alterations in gut microbiota that may support intestinal homeostasis. Furthermore, significant changes in levels of branched-chain amino acids in FDRs compared to CeD patients indicated their increased utilization for enterocytes renewal, upregulation of tight junction proteins and modulating immune response to maintain villous architecture. Our data showed that FDRs exhibit a specific metabolic signature that may represent an adaptive response aimed at maintaining intestinal homeostasis and mucosal integrity despite genetic predisposition.
Background
Celiac disease (CeD) is an autoimmune enteropathy with a genetic predisposition observed in first-degree relatives (FDRs) of affected patients. While a significant portion of FDRs carry HLA-DQ2/DQ8 haplotypes, only 7.5% develop enteropathy, indicating potential protective mechanisms. This study aims to explore the metabolomic differences in FDRs to understand biochemical pathways that may contribute to maintaining intestinal integrity.
Methods
The study employed a comparative analysis of the metabolome from small intestinal mucosal biopsies, blood plasma, and urine samples from serologically negative FDRs (n=50), CeD patients (n=64), and controls (disease controls, n=35; healthy controls, n=32). Proton NMR spectroscopy was utilized for metabolomic profiling, with both univariate and multivariate statistical analyses applied to assess differences.
Results
The metabolic profiles of FDRs differed significantly from both CeD patients and controls. Specific metabolites such as myo-inositol, fumarate, formate, and tyrosine were identified as elevated in FDRs, suggesting their roles in immune modulation and intestinal homeostasis.
Interpretation
The findings indicate that FDRs exhibit a unique metabolic signature that may represent an adaptive response to maintain intestinal health despite genetic predisposition. While the results are statistically significant, the clinical relevance of these metabolic changes remains to be established. Confounding factors include the reliance on metabolomic data without direct clinical outcomes and the limited sample size.
Key findings
- Higher myo-inositol and fumarate in the mucosa of FDRs compared to CeD patients and controls.
- Elevated formate and tyrosine levels in the intestinal mucosa of FDRs compared to both CeD patients and controls.
- Significant changes in levels of branched-chain amino acids in FDRs compared to CeD patients.
Limitations
- small n=50 for FDRs
- no direct clinical outcomes reported
- comparative study design may limit causal inferences
- reliance on metabolomic data without functional validation